-
1.发明申请公开(公告)号：US20190209529A1
公开(公告)日：2019-07-11
申请号：US16354764
申请日：2019-03-15
Applicant: Swati NAGAR , Sandip P. MEHTA , Manish UMRETHIA , Jayanta Kumar MANDAL
Inventor： Swati NAGAR , Sandip P. MEHTA , Manish UMRETHIA , Jayanta Kumar MANDAL
CPC classification number: A61K31/423 , A61K9/0053 , A61K9/0095 , A61K9/10 , A61K47/12 , A61K47/24 , A61K47/26 , A61K47/36 , A61K47/38
Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.
-
2.发明申请公开(公告)号：US20100248376A1
公开(公告)日：2010-09-30
申请号：US12748864
申请日：2010-03-29
Applicant: Samir SHAH , Keyur PATEL , Sanjay DASH , Kuldeep Dilip KARNIK , Ashish SEHGAL , Bhavesh Vallabhabhai PATEL , Jayanta Kumar MANDAL
Inventor： Samir SHAH , Keyur PATEL , Sanjay DASH , Kuldeep Dilip KARNIK , Ashish SEHGAL , Bhavesh Vallabhabhai PATEL , Jayanta Kumar MANDAL
IPC: G01N33/20
CPC classification number: G01N33/84 , A61K9/0019 , A61K31/7016 , A61K33/26 , A61K45/06 , G01N2400/00 , Y10T436/143333 , Y10T436/15 , A61K2300/00
Abstract: The present disclosure relates to an in vitro method for measuring the T75 of reduction kinetics of iron from Fe+3 to Fe+2 in an iron-sucrose complex and hence assessing the bioequivalency of iron-sucrose composition. According to the disclosed method, T75 of reduction kinetics of iron in an iron-sucrose complex in between 25 to 50 minutes indicates bioequivalent iron-sucrose composition.
Abstract translation: 本公开内容涉及用于测量铁 - 蔗糖复合物中铁从Fe + 3至Fe + 2的还原动力学的T75的体外方法，因此评估铁 - 蔗糖组合物的生物等效性。 根据所公开的方法，在铁 - 蔗糖复合物中铁的还原动力学T 25在25至50分钟之间表示生物等效的铁 - 蔗糖组成。
-
公开(公告)号：US20090196923A1
公开(公告)日：2009-08-06
申请号：US12303021
申请日：2007-04-23
Applicant: Jayanta Kumar Mandal , Nitesh Nalinchandra Pandya , Sumitra Ashok Pillai , Kirti Bansidhar Maheshwari
Inventor： Jayanta Kumar Mandal , Nitesh Nalinchandra Pandya , Sumitra Ashok Pillai , Kirti Bansidhar Maheshwari
CPC classification number: A61K9/4808 , A61K9/1652 , A61K9/2027 , A61K9/2054 , A61K9/5026 , A61K9/5047 , A61K31/00 , A61K31/55
Abstract: The present invention relates to pharmaceutical formulation of antiepileptic drug preferably oxcarbazepine. The formulation comprises multiple tablets or pellets of immediate release or controlled release nature, which are filled, inside the capsule to provides drug effect for 24 hours and is suitable for once a day administration. The patent also provides process of preparation of the dosage form.
Abstract translation: 本发明涉及抗癫痫药物的药物制剂，优选奥卡西平。 制剂包含立即释放或控制释放性质的多个片剂或丸剂，其填充在胶囊内以提供药物效应24小时，并且适合于每天一次给药。 该专利还提供了剂型的制备方法。
-
公开(公告)号：US20100267824A1
公开(公告)日：2010-10-21
申请号：US12742378
申请日：2008-11-11
Applicant: Ashish Sehgal , Bhavesh Vallabhabhai Patel , Jayanta Kumar Mandal
Inventor： Ashish Sehgal , Bhavesh Vallabhabhai Patel , Jayanta Kumar Mandal
IPC: A61K31/282 , A61P35/00
CPC classification number: A61K31/282 , A61K9/0019 , A61K31/555 , A61K33/24 , A61K47/26
Abstract: The present invention relates to a stable parenteral composition of oxaliplatin having pH range in between 3 to 4.5, which comprises of a solution of oxaliplatin in water wherein the said pH is attained by sparging of carbon dioxide in the composition. Further, a method for the preparation of oxaliplatin composition of the present invention is also disclosed.
Abstract translation: 本发明涉及pH范围在3至4.5之间的奥沙利铂的稳定肠胃外组合物，其包含奥沙利铂在水中的溶液，其中所述pH通过在组合物中喷射二氧化碳而达到。 此外，还公开了本发明的奥沙利铂组合物的制备方法。
-
公开(公告)号：US20090275647A1
公开(公告)日：2009-11-05
申请号：US12259634
申请日：2008-10-28
Applicant: Ashish SEHGAL , Bhavesh PATEL , Jayanta Kumar MANDAL
Inventor： Ashish SEHGAL , Bhavesh PATEL , Jayanta Kumar MANDAL
IPC: A61K31/337
CPC classification number: A61K9/0019 , A61K9/08 , A61K31/337 , A61K47/10
Abstract: A stable, absolutely ethanol free composition of docetaxel that prevents alcoholic intoxication or anaphylactic shock. The composition can be in the form of a stable injectable composition that includes a taxane derivative, wherein the composition includes a mixture of docetaxel, one or more stabilizer, one or more surfactant, or more co-solvent and water for injection wherein the composition is absolutely free of ethanol.
Abstract translation: 一种稳定，绝对无乙醇的多西他赛组合物，可防止酒精中毒或过敏性休克。 组合物可以是稳定的可注射组合物的形式，其包括紫杉烷衍生物，其中组合物包括多西紫杉醇，一种或多种稳定剂，一种或多种表面活性剂或更多共溶剂和注射用水的混合物，其中组合物为 绝对没有乙醇。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US08058076B2
公开(公告)日：2011-11-15
申请号：US12748864
申请日：2010-03-29
Applicant: Samir Shah , Keyur Patel , Sanjay Dash , Kuldeep Dilip Karnik , Ashish Sehgal , Bhavesh Vallabhabhai Patel , Jayanta Kumar Mandal
Inventor： Samir Shah , Keyur Patel , Sanjay Dash , Kuldeep Dilip Karnik , Ashish Sehgal , Bhavesh Vallabhabhai Patel , Jayanta Kumar Mandal
IPC: G01N33/20
CPC classification number: G01N33/84 , A61K9/0019 , A61K31/7016 , A61K33/26 , A61K45/06 , G01N2400/00 , Y10T436/143333 , Y10T436/15 , A61K2300/00
Abstract: The present disclosure relates to an in vitro method for measuring the T75 of reduction kinetics of iron from Fe+3 to Fe+2 in an iron-sucrose complex and hence assessing the bioequivalency of iron-sucrose composition. According to the disclosed method, T75 of reduction kinetics of iron in an iron-sucrose complex in between 25 to 50 minutes indicates bioequivalent iron-sucrose composition.
Abstract translation: 本公开内容涉及用于测量铁 - 蔗糖复合物中铁从Fe + 3至Fe + 2的还原动力学的T75的体外方法，因此评估铁 - 蔗糖组合物的生物等效性。 根据所公开的方法，在铁 - 蔗糖复合物中铁的还原动力学T 25在25至50分钟之间表示生物等效的铁 - 蔗糖组成。
-
7.发明申请SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER 审中-公开含有通道的苯并噻嗪衍生物的持续释放剂量形式公开(公告)号：US20100178333A1
公开(公告)日：2010-07-15
申请号：US12063812
申请日：2007-01-23
IPC: A61K9/52 , A61K9/14 , A61K9/22 , A61K31/554 , A61P25/18
CPC classification number: A61K9/2846 , A61K9/1635 , A61K9/1652 , A61K31/54
Abstract: Once a day sustained release solid oral dosage form of phenothiazine derivative preferably the dibenzothiazepine derivative and their pharmaceutically acceptable salts comprising of a channelizer, rate controlling polymer and suitable pharmaceutically acceptable excipients. The formulation of the present invention is in the form of tablet or capsule which provides a sustained drug action upto 24 hours upon single dose administration.
Abstract translation: 一天一次持续释放固体口服剂型的吩噻嗪衍生物，优选二苯并硫氮杂衍生物及其药学上可接受的盐，其包含通道剂，速率控制聚合物和合适的药学上可接受的赋形剂。 本发明的制剂是片剂或胶囊的形式，其在单剂量给药时提供持续的药物作用直至24小时。
-
公开(公告)号：US20180325813A1
公开(公告)日：2018-11-15
申请号：US15774073
申请日：2016-10-27
Applicant: Jayanta Kumar MANDAL , FTF Pharma Private Limited
Inventor： Jayanta Kumar Mandal , Henil Alpeshbhai PATEL , P. KANTEEPAN
CPC classification number: A61K9/0053 , A61K9/08 , A61K9/10 , A61K31/401 , A61K47/02 , A61K47/14 , A61K47/26
Abstract: The present invention provides pharmaceutical oral solution composition of ACE inhibitor. The oral solution composition comprises of ACE inhibitor with 5-9 pH and other pharmaceutical excipients having improved stability and palatability.
-
公开(公告)号：US20130303464A1
公开(公告)日：2013-11-14
申请号：US13991325
申请日：2011-12-05
Applicant: Pankaj Patel , Bhavesh Patel , Ashish Sehgal , Jayanta Kumar Mandal
Inventor： Pankaj Patel , Bhavesh Patel , Ashish Sehgal , Jayanta Kumar Mandal
IPC: A61K38/08
CPC classification number: A61K38/08 , A61K9/0019 , A61K38/09 , A61K47/12
Abstract: The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pharmaceutical preparation.
Abstract translation: 本发明公开了一种含有西曲瑞克或其药学上可接受的盐的稳定的即用型水性药物制剂，其中制剂不含任何表面活性剂。 此外，本发明公开了制备所述稳定即用型水性药物制剂的方法。
-
10.发明申请公开(公告)号：US20120252835A1
公开(公告)日：2012-10-04
申请号：US13431279
申请日：2012-03-27
Applicant: Harsh RAJPUT , Sandeep MEHTA , Pankaj PATEL , Bhavesh PATEL , Ashish SEHGAL , Jayanta Kumar MANDAL
Inventor： Harsh RAJPUT , Sandeep MEHTA , Pankaj PATEL , Bhavesh PATEL , Ashish SEHGAL , Jayanta Kumar MANDAL
IPC: A61K31/4353 , A61P35/00
CPC classification number: A61K9/0019 , A61K31/436 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/20 , A61K47/22 , A61K47/26
Abstract: The present disclosure describes a stable composition of Temsirolimus for parenteral administration. The composition includes BHA or BHT as anti-oxidants and alcoholic solvent. The pH of the composition is below 5.0. The composition also can include a chelating agent and/or a surfactant. A method of producing the composition is also described.
Abstract translation: 本公开描述了用于胃肠外给药的稳定的西西里莫单抗。 该组合物包括BHA或BHT作为抗氧化剂和醇溶剂。 组合物的pH低于5.0。 组合物还可以包括螯合剂和/或表面活性剂。 还描述了制备该组合物的方法。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.009 seconds)
